Ray Y. Chen
YOU?
Author Swipe
View article: Optimization and Application of a T cell Antigen-Specific Activation Assay as Diagnostic and Treatment Monitoring Tool for Tuberculosis
Optimization and Application of a T cell Antigen-Specific Activation Assay as Diagnostic and Treatment Monitoring Tool for Tuberculosis Open
Mycobacteria-specific T cell activation has been shown to be a robust biomarker of recent Mycobacterium tuberculosis ( M.tb ) infection, disease progression, and tuberculosis (TB) disease. We have termed an intracellular cytokine staining-…
View article: Investigating immune amnesia after measles virus infection in two West African countries: A study protocol
Investigating immune amnesia after measles virus infection in two West African countries: A study protocol Open
“Investigation of Immune Amnesia Following Measles Infection in Select African Regions” (ClinicalTrials.gov Identifier: NCT06153979) is a prospective, observational, longitudinal study being conducted in two West African countries; Guinea …
View article: Treatment outcomes of pulmonary TB in adults in Indonesia
Treatment outcomes of pulmonary TB in adults in Indonesia Open
BACKGROUNDAchieving the goal of Ending TB requires a treatment success rate of ≥90%, a challenging target for Indonesia. To understand outcomes and associated factors for unfavourable outcomes, we analysed prospective multicentre study dat…
View article: Investigating immune amnesia after measles virus infection in two West African countries: A study protocol Short Title - Investigating immune amnesia in two West African countries
Investigating immune amnesia after measles virus infection in two West African countries: A study protocol Short Title - Investigating immune amnesia in two West African countries Open
“Investigation of Immune Amnesia Following Measles Infection in Select African Regions” ( ClinicalTrials.gov Identifier: NCT06153979 ) is a prospective, observational, longitudinal study being conducted in two West African countries, Guine…
View article: Surveillance and agnostic capture sequencing of samples from individuals with rash-associated illness in Mali indicates regional transmission of measles virus from West and Central Africa
Surveillance and agnostic capture sequencing of samples from individuals with rash-associated illness in Mali indicates regional transmission of measles virus from West and Central Africa Open
Measles is vaccine-preventable extremely contagious disease caused by the measles virus. High vaccination coverage is needed to prevent outbreaks of disease. Although molecular surveillance of measles is critical to characterize outbreaks …
View article: PET/CT guided tuberculosis treatment shortening: a randomized trial
PET/CT guided tuberculosis treatment shortening: a randomized trial Open
Six months of chemotherapy using current agents is standard of care for pulmonary, drug-sensitive tuberculosis (TB), even though some are believed to be cured more rapidly and others require longer therapy. Understanding what factors deter…
View article: A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial
A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial Open
New tuberculosis treatments are needed to address drug resistance, lengthy treatment duration and adverse reactions of available agents. GSK3036656 (ganfeborole) is a first-in-class benzoxaborole inhibiting the Mycobacterium tuberculosis l…
View article: Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis
Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis Open
FDG-PET/CT imaging correlates with long-term outcomes during early bactericidal activity testing of tuberculosis drugs in patients.
View article: Predicting TB treatment outcomes using baseline risk and treatment response markers: developing the PredictTB early treatment completion criteria
Predicting TB treatment outcomes using baseline risk and treatment response markers: developing the PredictTB early treatment completion criteria Open
Standard treatment of drug-sensitive pulmonary tuberculosis requires six months of treatment. Several randomized clinical trials have attempted to shorten treatment to four months using various strategies but thus far all have failed. The …
View article: Neurotuberculosis: Control of Steroid-Refractory Paradoxical Inflammatory Reaction With Ruxolitinib
Neurotuberculosis: Control of Steroid-Refractory Paradoxical Inflammatory Reaction With Ruxolitinib Open
Paradoxical inflammatory reactions associated with treatment of neurotuberculosis can lead to severe morbidity and mortality and may not be controlled by steroids alone. We report the use of the Janus kinase inhibitor ruxolitinib to treat …
View article: Recent key advances in human immunodeficiency virus medicine and implications for China
Recent key advances in human immunodeficiency virus medicine and implications for China Open
In this article we summarize several recent major developments in human immunodeficiency virus treatment, prevention, outcome, and social policy change. Updated international guidelines endorse more aggressive treatment strategies and safe…
View article: Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis
Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis Open
We read with interest the papers by Tiberi et al. [1, 2] describing the effectiveness of meropenem/clavulanate in treating multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) patients. In these analyses, 96 pat…
View article: Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial
Using biomarkers to predict TB treatment duration (Predict TB): a prospective, randomized, noninferiority, treatment shortening clinical trial Open
Background: By the early 1980s, tuberculosis treatment was shortened from 24 to 6 months, maintaining relapse rates of 1-2%. Subsequent trials attempting shorter durations have failed, with 4-month arms consistently having relapse rates of…
View article: Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis
Evaluation of a Rapid Molecular Drug-Susceptibility Test for Tuberculosis Open
This investigational assay accurately detected M. tuberculosis mutations associated with resistance to isoniazid, fluoroquinolones, and aminoglycosides and holds promise as a rapid point-of-care test to guide therapeutic decisions for pati…
View article: Severe Paradoxical Reaction During Treatment of Disseminated Tuberculosis in a Patient With Neutralizing Anti-IFNγ Autoantibodies
Severe Paradoxical Reaction During Treatment of Disseminated Tuberculosis in a Patient With Neutralizing Anti-IFNγ Autoantibodies Open
Interferon-gamma (IFNγ) neutralizing autoantibodies are associated with disseminated nontuberculous mycobacterial infections. We report a previously healthy Thai woman with disseminated tuberculosis and high-titer IFNγ-neutralizing autoant…
View article: A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets
A Sterilizing Tuberculosis Treatment Regimen Is Associated with Faster Clearance of Bacteria in Cavitary Lesions in Marmosets Open
Shortening the lengthy treatment duration for tuberculosis patients is a major goal of current drug development efforts. The common marmoset develops human-like disease pathology and offers an attractive model to better understand the basi…